Maybe the English are buying today :-)
biz.yahoo.com
Tuesday May 1, 12:29 pm Eastern Time
Press Release
Vasomedical's EECP Technology Featured in the Times of London
WESTBURY, N.Y.--(BW HealthWire)--May 1, 2001--Vasomedical, Inc. (Nasdaq: VASO - news) announced today that an article on EECP® enhanced external counterpulsation by David Charter, health correspondent for The Times of London, was published in yesterday's edition of the renowned British newspaper.
According to the article, twelve of fifteen patients treated to date at Hammersmith Hospital in London for chronic angina or chest pain have reported significant and lasting improvements in their condition. The EECP Center at Hammersmith has received over 140 phone calls since the article appeared. The article also reported that similarly impressive results had been achieved at the Hull Royal Infirmary in the north of England.
Commenting on the publication of yesterday's article, Douglas A. Goldman, Vice President of Marketing and Business Development for Vasomedical said, ``The article underscores the increasing visibility that EECP is receiving in the UK and the rest of Europe and the extent to which interest among the general population in this noninvasive method for treating coronary artery disease is growing.'' He added, ``We believe EECP has important implications for the management of coronary artery disease through the National Health System (NHS) in the UK given the long waiting lists for bypass surgery and angioplasty. Patients in the UK often wait 6-12 months for such procedures.''
Vasomedical recently announced that it would begin to expand its marketing presence in Europe by participating in three major cardiovascular conferences there later this spring, including the British Cardiac Society in Manchester, United Kingdom, May 22-24, the Euro-Paris Course on Revascularization in Paris, France, May 22-25; and the European Society of Cardiology's Heart Failure Conference in Barcelona, Spain, June 9-12.
EECP is a non-invasive, outpatient therapy for angina that utilizes pneumatic cuffs to compress the lower extremities in time with a patient's heartbeat. The therapy reduces levels of angina by improving circulation in areas of the heart deprived of adequate blood supply and restoring vascular function. The therapy has been scientifically validated over the past several years, and has been approved for Medicare reimbursement in the United States.
Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting external counter pulsation systems based on the Company's proprietary technology currently indicated for use in cases of angina, cardiogenic shock and acute myocardial infarction. EECP® is a registered trademark for Vasomedical's enhanced external counterpulsation system. This system is now in use at major medical centers, including the Beth Israel Medical Center - New York City, Christ Hospital and Medical Center, the Cleveland Clinic, Texas Heart Institute, Johns Hopkins, JFK Medical Center-Atlantis, FL, University Hospital at UMDNJ/New Jersey Medical School, Mayo Clinic, the Miami Heart Institute and the Ochsner Foundation Hospital, as well as medical centers affiliated with Columbia University, the University of Pittsburgh, the University of California at San Diego, the University of California at San Francisco, University of Florida at Gainesville, State University of New York at Stony Brook and the University of Virginia. The Company provides hospitals, clinics and private practices with EECP® equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. Additional information is available on the Company's website at www.vasomedical.com.
Except for historical information contained in this release, the matters discussed are forward looking statements that involve risks and uncertainties. When used in this release, words such as ``anticipate,'' ``believe,'' ``estimate,'' ``expect'' and ``intend'' and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.
--------------------------------------------------------------------------------
Contact:
Vasomedical, Inc., Westbury
D. Michael Deignan, 516/997-4600 Ext. 155
Douglas A. Goldman, 516/997-4600 Ext. 163
www.vasomedical.com
Investor Relations:
516/997-4600 Ext. 790
investorrelations@vasomedical.com |
